Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-11-27 |
Juno Therapeutics (USA - WA) |
vice president |
|
nomination |
Cancer - Oncology |
Nomination |
2017-11-27 |
Brammer Bio (USA - MA) |
manufacturing site in Cambridge |
|
opening of new premises |
Technology - Services |
Opening of new premises |
2017-11-14 |
Theradiag (France) Biogen (USA - MA) |
LISA TRACKER kits for monitoring Flixabi® (an infliximab biosimilar) |
|
collaboration |
|
Collaboration agreement |
2017-11-13 |
AdAlta (Australia) XL-protein (Germany) |
PASylation® technology applied to AD-114 |
fibrosis |
licensing |
Fibrotic diseases |
Licensing agreement |
2017-11-13 |
Crispr Therapeutics (Switzerland - UK) Casebia Therapeutics (UK) Curevac (Germany) |
Cas9 mRNA constructs |
liver diseases |
collaboration |
Hepatic diseases - Liver diseases |
Collaboration agreement |
2017-11-13 |
Homology Medicines (USA - MA) Novartis (Switzerland) |
gene editing technology |
|
R&D - research - development |
Technology - Services - Ophtalmological diseases - Hematological diseases |
Research agreement |
2017-11-12 |
|
|
|
|
|
Restructuring |
2017-11-10 |
Medivir (Sweden) |
vice president strategic business development |
|
nomination |
Infectious diseases |
Nomination |
2017-11-09 |
Dynacure (France) Ionis Pharmaceuticals (USA - CA) |
IONIS-DNM2-2.5Rx (Dyn101) |
centronuclear myopathy (CNM) |
licensing |
Rare diseases - Genetic diseases |
Licensing agreement |
2017-11-09 |
Avrobio (USA - MA) |
|
|
nomination |
Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases |
Nomination |
2017-11-09 |
Sangamo Therapeutics (USA - CA) |
head of technical operations and manufacturing |
|
nomination |
Rare diseases - Genetic diseases - Technology - Services |
Nomination |
2017-11-09 |
Sangamo Therapeutics (USA - CA) |
cGMP manufacturing facility, new headquarters |
|
construction of new premises |
Rare diseases - Genetic diseases - Technology - Services |
Construction of new premises |
2017-11-09 |
apceth (Germany) |
supervisory board |
|
nomination |
Technology - Services |
Nomination |
2017-11-08 |
Boehringer Ingelheim (Germany) Mina Therapeutics (UK) |
small activating RNA (“saRNA”) |
NASH (non-alcoholic steatohepatitis), fibrotic diseases |
licensing - development |
Fibrotic diseases - Hepatic diseases - Liver diseases |
Licensing agreement |
2017-11-06 |
VBL Therapeutics (Israel) NanoCarrier (Japan) |
VB-111 (ofranergene obadenovec) |
|
development - licensing - commercialisation |
Cancer - Oncology |
Licensing agreement |
2017-11-06 |
Adaptimmune (UK) |
U.K. headquarters |
|
opening of new premises |
Cancer - Oncology |
Opening of new premises |
2017-11-02 |
Genentech, a member of Roche group (USA - Switzerland) AC Immune (Switzerland) |
anti-Tau antibodies |
Alzheimer’s disease and other neurodegenerative disease |
R&D - research - development - commercialisation - licensing |
Neurodegenerative diseases |
Milestone |
2017-11-01 |
Merck&Co (USA - NJ) Samsung Biologics (South Korea) |
biopharmaceutical manufacturing and biologics process development.,biosimilar candidates (SB4 Enbrel (etanercept), SB2 Remicade (infliximab), SB5 Humira (adalimumab), SB3 Herceptin (trastuzumab), MK-1293 Lantus (insulin glargine) |
|
development, commercialisation |
Autoimmune diseases - Inflammatory diseases - Rheumatic diseases - Dermatological diseases - Digestive diseases |
Development agreement |
2017-10-31 |
Basilea Pharmaceutica (Switzerland) |
chief medical officer |
|
nomination |
Infectious diseases |
Nomination |
2017-10-30 |
AstraZeneca (UK) Mereo Biopharma (UK) |
AZD9668 |
alpha-1 antitrypsin deficiency (AATD) |
licensing |
Rare diseases - Genetic diseases - Respiratory diseases |
Licensing agreement |